

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Novo Nordisk A/S	12/07/2006
RECEIVING PARTY DATA	
Name:	Eli Lilly and Company
Street Address:	Lilly Corporate Center
Internal Address:	Patent Division
City:	Indianapolis
State/Country:	INDIANA
Postal Code:	46285
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	5968926
CORRESPONDENCE DATA	
Fax Number:	(317)276-3861
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	patents@lilly.com
Correspondent Name:	Eli Lilly and Company/ Linda Durbin
Address Line 1:	P.O. Box 6288
Address Line 2:	Patent Division
Address Line 4:	Indianapolis, INDIANA 46206-6288
ATTORNEY DOCKET NUMBER:	X-17577
NAME OF SUBMITTER:	Linda M. Durbin
Total Attachments: 2 source=X17577Assignment#page1.tif source=X17577Assignment#page2.tif	

CH \$40.00 5968926

500201503

PATENT
REEL: 018700 FRAME: 0097

ASSIGNMENT

WHEREAS Novo Nordisk A/S, having a place of business at Novo Allé, DK-2880 Bagsaerd, Denmark ("NOVO") by virtue of an assignment recorded on 30 Sep 1993, at reel 006722, frame 0136, NOVO is owner of the right, title and interest in an invention that is the subject of a patent application ("Application") which is entitled Antipsychotic Method, containing 38 pages and 0 drawings, and which:

☐ is being filed:

☒ was filed:

☐ in the United States Patent and Trademark Office

☐ in the United Kingdom Patent Office

☐ in the European Patent Office

☐ in the Spanish Patent Office as a European Application

☐ as an international application under the Patent Cooperation Treaty ("PCT"), with:

☒ United States Patent and Trademark Office acting as Receiving Office, or

☐ International Bureau acting as Receiving Office;

☐

on June 5, 1995, and accorded serial number 08/463,615;

and

WHEREAS, ELI LILLY AND COMPANY ("LILLY"), having a place of business at Lilly Corporate Center, Indianapolis, IN 46285 wishes to acquire the entire right, title and interest in and to all invention disclosed in such Application, and in, to and under any Letters Patent which may be obtained to said invention;

NOW, THEREFORE, pursuant to the Research Agreement between LILLY and NOVO dated December 24, 1987, by and between LILLY and NOVO, ("Research Agreement") or other good and valuable consideration, the receipt of which is hereby acknowledged, NOVO hereby sells, assigns, transfers and sets over unto LILLY, its successors and assigns NOVO's entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all

PATENT

REEL: 018700 FRAME: 0098

of the above to be held and enjoyed by the LILLY for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by NOVO had this Assignment and sale to LILLY not been made.

NOVO authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any foreign equivalent thereof, to issue any such Letters Patent which may be granted on the Application to LILLY as assignee of the entire right, title and interest therein and thereto.


For LILLY and its legal representative, NOVO covenants and agrees, in accordance with the terms of the Research Agreement between LILLY and NOVO, that NOVO has not granted to any others any license to make, use or sell any of such inventions, that NOVO's right, title and interest in such inventions has not been encumbered, that NOVO has good right and title to sell and assign the same, and that NOVO will not execute any instrument in conflict therewith.

I have executed this assignment on the 7th day of December, 2006.



Representative for Novo Nordisk A/S

Title ~~Mads Krogsgaard Thomsen~~
Chief Science Officer
Novo Nordisk A/S



Representative for Novo Nordisk A/S

Lise Kingo
Executive vice president and chief of staffs
Corporate Relations

Title _____

/Lake